1. Home
  2. AEYE vs MAIA Comparison

AEYE vs MAIA Comparison

Compare AEYE & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AudioEye Inc.

AEYE

AudioEye Inc.

HOLD

Current Price

$7.12

Market Cap

90.5M

Sector

Technology

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.28

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEYE
MAIA
Founded
2005
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.5M
79.0M
IPO Year
2011
2022

Fundamental Metrics

Financial Performance
Metric
AEYE
MAIA
Price
$7.12
$1.28
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$14.63
N/A
AVG Volume (30 Days)
180.8K
553.8K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
30.56
33.33
EPS
N/A
N/A
Revenue
$40,311,000.00
N/A
Revenue This Year
$11.12
N/A
Revenue Next Year
$11.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.52
N/A
52 Week Low
$5.31
$0.87
52 Week High
$16.39
$3.19

Technical Indicators

Market Signals
Indicator
AEYE
MAIA
Relative Strength Index (RSI) N/A 46.47
Support Level N/A $1.25
Resistance Level N/A $1.48
Average True Range (ATR) 0.00 0.07
MACD 0.00 -0.00
Stochastic Oscillator 0.00 26.32

Price Performance

Historical Comparison
AEYE
MAIA

About AEYE AudioEye Inc.

AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: